Posted by Michael Wonder on 19 Jan 2023
Innovent announces inclusion in the China National Reimbursement Drug List of Tyvyt in two new indications, olverembatinib for the first listing, Byvadsa, Halpryza and Sulinno in multiple new indications
18 January 2023 - Innovent Biologics today announced that, five products (including new indications) of the company have been included in the updated National Reimbursement Drug List (2022 version).
This includes two additional indications of PD-1 inhibitor Tyvyt (sintilimab injection) were included (negotiation list); olverembatinib was included for the first time (negotiation list); multiple additional indications of Byvasda (bevacizumab), Halpryza (rituximab) and Sulinno (adalimumab) were included (general list).
